Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06462781 · ClinicalTrials.gov registry record · Phase 1
Localized Injection of Lidocaine and Glucocorticoid for Headache Treatment Phase 1
A Phase 1 study, sponsored by The Cooper Health System.
- Completed
- Registry status
- Phase 1
- Development phase
- 10
- Enrollment target
NCT06462781: Completed Phase 1 study, sponsored by The Cooper Health System.
NCT06462781 is a Phase 1 study that has completed, run by The Cooper Health System. The registered enrollment target is 10 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (83% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06462781, a Phase 1 study, has completed, sponsored by The Cooper Health System.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 10 participants
- Enrollment target
Study Summary
The goal of this clinical trial is to test whether injecting lidocaine and steroids into two blood vessels of the brain can help treat chronic headaches (migraines). The main questions this study aims to answer: is this treatment safe for chronic migraine patients? Participants will: * Be treated once with lidocaine and steroid infused into the middle meningeal arteries (two blood vessels in the brain). * Attend appointments scheduled 1 week, 6 weeks, and 12 weeks after the treatment for a checkup. * Keep a log of their symptoms.
Primary Outcome
Reported adverse events classified using MedDRA and CTCAE, including all events, treatment-related events, and any serious adverse event
Interventions
- DRUG Lidocaine hydrochloride
- DRUG Methylprednisolone sodium succinate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2024-03-15 |
| Est. Completion | 2025-06-01 |
| Phase | Phase 1 |
What the finished NCT06462781 record still lists
NCT06462781 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 10 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (83% lower).
The record links to 0 conditions, and to 2 interventions - of which Lidocaine hydrochloride is the first listed.
NCT06462781 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT06462781 about?
NCT06462781 is a clinical study titled "Localized Injection of Lidocaine and Glucocorticoid for Headache Treatment Phase 1". The goal of this clinical trial is to test whether injecting lidocaine and steroids into two blood vessels of the brain can help treat chronic headaches (migraines). The main questions this study aims to answer: is this treatment safe for chronic migraine patients? Participants will: * Be treated...
What is the current status of trial NCT06462781?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 10 participants. The study started on 2024-03-15. Estimated completion is 2025-06-01.
What interventions are being tested in trial NCT06462781?
The interventions under investigation include: Lidocaine hydrochloride (DRUG), Methylprednisolone sodium succinate (DRUG).
Who is sponsoring clinical trial NCT06462781?
This trial is sponsored by The Cooper Health System, which has 39 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06462781's enrollment target sits among peer trials
10 1913th of 2000 higher than 46 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00623389 · 10 participants · NA
Evaluation of an Advanced Lower Extremity Neuroprostheses
- NCT01241864 · 10 participants · Phase 2
Islet Transplantation in Type 1 Diabetic Kidney Allograft
- NCT01293214 · 10 participants · NA
Vascularized Composite Allotransplantation for Multiple Extremity Amputations
- NCT01474148 · 10 participants · NA
A Neuroprosthesis for Seated Posture and Balance
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI